Brokerages Set Traws Pharma, Inc. (NASDAQ:TRAW) Target Price at $8.00

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have earned a consensus rating of “Reduce” from the five brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $1.00.

TRAW has been the subject of several recent research reports. LADENBURG THALM/SH SH lowered shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Wall Street Zen raised shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Citigroup lowered shares of Traws Pharma to a “neutral” rating in a research report on Monday. HC Wainwright reissued a “negative” rating and issued a $1.00 price target on shares of Traws Pharma in a research report on Thursday. Finally, Weiss Ratings lowered shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 29th.

Traws Pharma Price Performance

NASDAQ:TRAW opened at $0.85 on Monday. Traws Pharma has a 12-month low of $0.64 and a 12-month high of $3.27. The firm has a market capitalization of $8.64 million, a PE ratio of -0.50 and a beta of 1.45. The firm has a 50-day moving average price of $1.41 and a 200 day moving average price of $1.69.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.39. On average, research analysts expect that Traws Pharma will post -1.58 EPS for the current year.

Insider Transactions at Traws Pharma

In other Traws Pharma news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was purchased at an average price of $1.67 per share, with a total value of $998,207.43. Following the completion of the transaction, the insider directly owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.57% of the stock is owned by company insiders.

Institutional Trading of Traws Pharma

Several hedge funds have recently modified their holdings of TRAW. Two Sigma Investments LP increased its holdings in shares of Traws Pharma by 37.1% during the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after buying an additional 5,955 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after buying an additional 18,213 shares in the last quarter. State Street Corp acquired a new stake in shares of Traws Pharma during the fourth quarter worth approximately $29,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of Traws Pharma by 121.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after buying an additional 400,000 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Traws Pharma during the fourth quarter worth approximately $175,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.